China expands its manufacturing role for biopharma’s new drugs
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging …
Post
-
-
Aptar Pharma and Macquarie University partner on drug delivery project
Aptar Pharma is collaborating with Macquarie University in a partnership that will see the drug delivery specialist and Australian institution …
-
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and …
-
Roche and Earendil forge $1.5bn bispecific discovery deal
Roche-owned Genentech has penned a blockbuster deal with Earendil Labs to discover and develop bispecific antibodies for oncology. In exchange for …
-
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to …
-
China expands its manufacturing role for biopharma’s new drugs
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging …
-
Aptar Pharma and Macquarie University partner on drug delivery project
Aptar Pharma is collaborating with Macquarie University in a partnership that will see the drug delivery specialist and Australian institution …
-
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and …
-
Roche and Earendil forge $1.5bn bispecific discovery deal
Roche-owned Genentech has penned a blockbuster deal with Earendil Labs to discover and develop bispecific antibodies for oncology. In exchange for …
-
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to …
-
FDA approves Lilly’s Onswik for type 2 diabetes in adults
The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal …
-
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
Eli Lilly has partnered with China-based InnoCare Pharma in a five-drug strong research and license pact. As per the deal, Lilly …
-
Australia starts investigation into OpenAI Medicare breach
The Australian government has initiated a review into a hacking incident in which tech giant OpenAI’s artificial intelligence (AI) model …
-
Podcast: How Sandoz plans to harness its “golden decade”
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap …
-
Enveda nabs $311m to progress nature-derived drug pipeline
Colorado-based biotech Enveda has closed a $311m Series E funding round to advance its pipeline of artificial intelligence (AI)-discovered therapies …
